RxDoctor Payments Data

Alla Osipchuk, APRN

Adult Health · Caldwell, IDNPI 1891116653

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Abbott at 49.0% of the total. Reporting peaked in 2021 at $796 and has fallen 69.3% since, to $245 in 2025.

$2,282in general payments, 2019–2025

Across 213 payments — averaging $10.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$298
  • Medtronic$291
  • AbbVie$125
  • Collegium Pharmaceutical, Inc.$114
  • Pfizer$110
  • plus $224 from 8 others

What the payments were for

  • Food & beverage$2,282100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,282 in reported general payments places this provider in the 80th percentile of 38 adult health providers in Idaho.

See all adult health providers in Idaho

Medicare billing

Part B allowed, 2024
$40,366
Medicare patients
118
Services billed
754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide12$27,664
Aimovig AutoinjectorErenumab-Aooe20$14,927
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen485$13,219
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen240$10,287
Pregabalin140$8,985
Xtampza ErOxycodone Myristate12$8,957
MovantikNaloxegol Oxalate19$8,784
Ajovy SyringeFremanezumab-Vfrm11$7,725
Diclofenac Sodium19$7,208
Oxycodone Hcl177$5,773
OxycontinOxycodone Hcl18$4,483
Morphine Sulfate ErMorphine Sulfate151$3,468
Hydromorphone Hcl118$3,351
Buprenorphine13$3,327
Gabapentin166$2,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$298$27,66412 claims
Collegium Pharmaceutical, Inc.Xtampza Er$114$8,95712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 38 adult health providers in Idaho.

Other adult health in Caldwell

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →